Septerna, Inc. Common Stock Cash Flow Conversion Efficiency
Septerna, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Septerna, Inc. Common Stock (SEPN) has a cash flow conversion efficiency ratio of -0.068x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-25.63 Million) by net assets ($378.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Septerna, Inc. Common Stock (2022–2025)
Cash flow conversion efficiency of Septerna, Inc. Common Stock from 2022 to 2025. This chart illustrates how Septerna, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View SEPN share price today for real-time trading data and today's change.
Septerna, Inc. Common Stock Cash Flow Conversion Ratio Explained
Septerna, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Septerna, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Septerna, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see how much is Septerna, Inc. Common Stock worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Greatech Technology Bhd
KLSE:0208
|
0.034x |
|
Mineros SA
TO:MSA
|
0.098x |
|
Pfeiffer Vacuum Technology AG
F:PFV
|
0.099x |
|
Nuvation Bio Inc
NYSE:NUVB
|
-0.020x |
|
Clover Health Investments Corp
NASDAQ:CLOV
|
0.318x |
|
Tootsie Roll Industries Inc
NYSE:TR
|
0.012x |
|
Poly Medicure Limited
NSE:POLYMED
|
0.029x |
|
Ruentex Engineering & Construction Co Ltd
TW:2597
|
-0.059x |
Annual Cash Flow Conversion Efficiency for Septerna, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Septerna, Inc. Common Stock from 2022 to 2025. Review Septerna, Inc. Common Stock (SEPN) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $381.93 Million | $110.19 Million | 0.289x | +279.62% |
| 2024-12-31 | $420.05 Million | $-67.47 Million | -0.161x | -115.92% |
| 2023-12-31 | $-38.37 Million | $-38.72 Million | 1.009x | +91.40% |
| 2022-12-31 | $-44.20 Million | $-23.30 Million | 0.527x | -- |
About Septerna, Inc. Common Stock
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 … Read more